Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical RGL-2102 for diabetic foot ulcers (II/III seamless randomized trial)
CTR20254640Phase 3Active
- Sponsor
- Neurophth
- Start
- Dec 2025
- Countries
- 1
01
Overview
A Phase 3 trial of RGL-2102 in diabetic foot ulcer (DFU), sponsored by Neurophth. Started Dec 2025; status: active.
02
Drugs
RGL-2102
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on CTR20254640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254640.